Calistoga Pharmaceuticals
Calistoga Pharmaceuticals develops therapeutic oral medicines for patients suffering from cancer and inflammatory diseases.
Business Model:
Revenue: $0
Employees: 1-10
Rankings
Industries / Tags:
Detailed Calistoga Pharmaceuticals Information
Calistoga Pharmaceuticals was acquired by
Gilead Sciences.
The acquisition happend on 2011-02-22.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City: Seattle
State: Washington
Zip:
Country: United States
Financial Info
Stage:
series c
Raised Last:
$40M
Raised Total:$97M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals&s; small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals&s; lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals&s; product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2009 | Series A | $1M | 3/2007 | Series A | 4 | $21M |
Frazier Healthcare Partners Three Arch Partners Amgen Ventures Alta Partners Frazier Healthcare Partners |
6/2010 | Series C | 6 | $40M |
Latterell Venture Partners Amgen Ventures Alta Partners Quogue Capital Three Arch Partners Frazier Healthcare Partners Quogue Capital Latterell Venture Partners Amgen Ventures Alta Partners Quogue Capital Three Arch Partners Frazier Healthcare Partners Quogue Capital |
5/2009 | Series B | 4 | $30M |
Alta Partners Frazier Healthcare Partners Amgen Ventures Three Arch Partners Alta Partners Frazier Healthcare Partners Amgen Ventures Three Arch Partners |
1/2008 | Series A | 4 | $5.2M |
Three Arch Partners Frazier Technology Ventures Amgen Ventures Alta Partners |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
